After serving as CEO, Stephen P. MacMillan owned shares in Boston Scientific, which had values that saw some fluctuation. In May 2020, his holdings were valued at around $285,000 but had climbed to about $655,680 by October 2024. This range...

After serving as CEO, Stephen P. MacMillan owned shares in Boston Scientific, which had values that saw some fluctuation. In May 2020, his holdings were valued at around $285,000 but had climbed to about $655,680 by October 2024. This range shows his active involvement in the market even after stepping down from his executive role at Stryker. From his peak wealth linked to Stryker's performance, his significant stock option grants reflect the serious commitments executives have with their companies. MacMillan navigated his post-CEO life maintaining connections with significant financial interests, indicating a steady engagement with the medical industry.